Search Results - "Bylow, Kathryn A."

Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma by Grivas, Petros D., Daignault, Stephanie, Tagawa, Scott T., Nanus, David M., Stadler, Walter M., Dreicer, Robert, Kohli, Manish, Petrylak, Daniel P., Vaughn, David J., Bylow, Kathryn A., Wong, Steven G., Sottnik, Joseph L., Keller, Evan T., Al‐Hawary, Mahmoud, Smith, David C., Hussain, Maha

“…BACKGROUND Angiogenesis contributes to the progression of urothelial carcinoma (UC). In the current study, the authors investigated the role of maintenance…”
Get full text

Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial by Hall, William A., Bedi, Meena, Kilari, Deepak, Bylow, Kathryn A., Burfeind, John, Johnstone, Candice, Siker, Malika, Currey, Adam, See, William A., Nelson, Ariel, Johnson, Scott, Straza, Michael, Lawton, Colleen A.F.

“…There remains limited data as to the feasibility, safety, and efficacy of higher doses of elective radiation therapy to the pelvic lymph nodes in men with…”
Get full text

TEMPORAL ARTERITIS: THE IMPORTANCE OF RECOGNIZING SENESCENT CHANGES VERSUS QUIESCENT DISEASE IN A TEMPORAL ARTERY BIOPSY by Bylow, Kathryn A., Brauner, Daniel J.

Get full text

Phase II Trial of Carboplatin and Paclitaxel in Papillary Renal Cell Carcinoma by Bylow, Kathryn A, Atkins, Michael B, Posadas, Edwin M, Stadler, Walter M, McDermott, David F

“…Abstract Background Cytotoxic chemotherapy has not been well investigated in non–clear-cell renal cell carcinoma (RCC). A phase II study was thus conducted to…”
Get full text

Impact of pre-treatment hemoglobin (Hgb) on outcomes in metastatic castration resistant prostate cancer (mCRPC) with lutetium-177-PSMA-617 (Lu-177) by Nelson, Ariel Ann, Riemersma, Kristin, Bylow, Kathryn A., Holt, Michael, Kilari, Deepak

“…e17065 Background: The Phase 3 VISION and TheraP trials excluded men with Hgb≤ 9 g/dL or blood transfusion within 30 days of Lu-177. Patients (pts) with mCRPC…”
Get full text

Disparities in medical oncology visit adherence among African American (AA) men with prostate cancer (pCa) by Nelson, Ariel Ann, Ladwig, Christina, Riemersma, Kristin, Bylow, Kathryn A., Kilari, Deepak

“…e18671 Background: AA patients (pts) with pCa tend to have worse outcomes when compared to Caucasians. Disparities in access to healthcare among AA pts with…”
Get full text

Immunohistochemical (IHC) subtypes of metastatic bladder cancer (mBC) using GATA3 and CK5/6 by Nelson, Ariel Ann, Molina Nunez, Mariel, Bylow, Kathryn A., Szabo, Aniko, Iczkowski, Kenneth, Kilari, Deepak

“…557 Background: Genomic analyses have identified that bladder cancers can be divided into distinct molecular subtypes: luminal and basal. IHC markers GATA3 and…”
Get full text

Impact of pre-existing anemia and/or packed red blood cell transfusion prior to Radium-223 administration on oncologic outcomes by Pierro, Michael, Nelson, Ariel Ann, Xie, John, Jang, Albert, Bylow, Kathryn A., Barata, Pedro C., Lawton, Colleen Anne, Kilari, Deepak

“…67 Background: Radium-223 (Ra-223), a targeted alpha-emitting radiopharmaceutical approved for the treatment of metastatic prostate cancer (mPC), can cause…”
Get full text

Predictors of response to platinum (Pt)-based chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) by Kilari, Deepak, Bylow, Kathryn A., Berlin, Kathryn E. K.

“…Abstract only e575 Background: Aggressive variant PC (AVPC) is a well-described subtype of PC which portends a poor prognosis. Studies have shown an increase…”
Get full text

A single-arm, open-label, phase 2 study evaluating pacritinib for patients with biochemical recurrence after definitive treatment for prostate cancer: Blast study by Kilari, Deepak, Szabo, Aniko, Hall, William A., Nelson, Ariel Ann, Johnson, Scott, Giever, Thomas A., Burfeind, John, Tolat, Parag, Bylow, Kathryn A., Iczkowski, Kenneth, Sun, Yunguang, Rui, Hallgeir, Thomas, James P., Nevalainen, Marja

“…Abstract only TPS220 Background: Androgen deprivation therapy (ADT) achieved with gonadotropin releasing hormone (GnRH) agonist or antagonist is considered the…”
Get full text

A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study by Kilari, Deepak, Szabo, Aniko, Bylow, Kathryn A., Alter, Robert S., Nelson, Ariel Ann, Lemke, Emily, Hall, William Adrian, Johnson, Scott, Langenstroer, Peter, Jacobsohn, Kenneth, Davis, Nancy B., Fung, Chunkit, Milowsky, Matthew I.

“…Abstract only TPS4591 Background: ABACUS and PURE-01 trials demonstrated the activity of single agent atezolizumab and pembrolizumab respectively as…”
Get full text

A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study by Kilari, Deepak, Szabo, Aniko, Tripathi, Abhishek, Paul, Asit K., Alter, Robert S., Bylow, Kathryn A., Nelson, Ariel Ann, Hall, William A., Langenstroer, Peter, Jacobsohn, Kenneth, Rini, Brian I., Van Veldhuizen, Peter J., Johnson, Scott, Davis, Nancy B., Fung, Chunkit, Milowsky, Matthew I.

“…TPS4618 Background: ABACUS and PURE-01 trials demonstrated the activity of single agent atezolizumab and pembrolizumab respectively as neoadjuvant therapy for…”
Get full text

Liver-directed therapy (LDT) for metastatic renal cell carcinoma (mRCC): Single center experience by Raychaudhuri, Ruben, Bylow, Kathryn A., Lea, William, Byun, John, Zellmer, Timothy, Burfeind, John D., Riese, Matthew John, Kilari, Deepak

“…Abstract only 681 Background: Liver metastases arising from RCC are common and signify a poor prognosis. Given the negative impact of liver metastases on…”
Get full text

Effect of β-hydroxy-β-methylbutyrate (HMB) on muscle strength in older men with prostate cancer (Pca) started on androgen deprivation therapy (ADT): Preliminary results of an open-label, randomized trial by Bylow, Kathryn A., Kilari, Deepak, Riese, Matthew John, Burfeind, John, Stolley, Melinda, Prost, Robert W, Musto, Kaylinn, Neilson, Raquel, Szabo, Aniko, Thomas, James P., Ng, Alexander V.

“…Abstract only 258 Background: ADT causes muscle weakness and wasting within 3 months (mo), causing older men on ADT to experience functional impairments and…”
Get full text

A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa): Tolerability and geriatric asssessment (GA) results by Zittel, Jason, Fung, Chunkit, Babu, Dilip Sankar, Guancial, Elizabeth A., Sahasrabudhe, Deepak M., Bylow, Kathryn A., Burfeind, John D., Musto, Kaylinn, Wang, Bokai, Patil, Amita, Messing, Edward M., Mohile, Supriya Gupta, Kilari, Deepak

“…Abstract only e16518 Background: Older men are at a high risk for adverse events (AEs) from androgen deprivation therapy (ADT). In this phase II study, we…”
Get full text

Emerging clinical phenotype of bone metastatic urothelial cancer (mUC): Association of early osseous metastases (EOM) and outcomes by Nelson, Ariel Ann, Cronk, Robert, Szabo, Aniko, Lemke, Emily, Giever, Thomas A., Burfeind, John D., Kilari, Deepak, Riese, Matthew John, Bylow, Kathryn A., Diamantopoulos, Leonidas Nikolaos, Khaki, Ali Raza, Nezami, Behtash, MacLennan, Gregory, Draves, Mary Ann, Goolamier, Gordon, Rosey, Samantha, Calaway, Adam, Grivas, Petros, Ponsky, Lee Evan, Hoimes, Christopher J.

“…Abstract only e17007 Background: Outcomes of patients (pts) with mUC with EOM have not thoroughly been described in the age of immuno-oncology. We hypothesized…”
Get full text

A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa) by Kilari, Deepak, Guancial, Elizabeth A., Sahasrabudhe, Deepak M., Bylow, Kathryn A., Burfeind, John D., Musto, Kaylinn, Feng, Changyong, Messing, Edward M., Mohile, Supriya Gupta, Fung, Chunkit

“…Abstract only 179 Background: Older men are at a high risk for adverse events (AEs) from androgen deprivation therapy (ADT). In prior studies, peripheral…”
Get full text

Abstract A034: Health-related quality of life among African American prostate cancer survivors enrolled in a lifestyle intervention program by Awoyinka, Iwalola, Flynn, Kathryn E., Banerjee, Anjishnu, Visotcky, Alexis, Aboagye, Sophia, Tovar, Margaret, Kilari, Deepak, Bylow, Kathryn A., Papanek, Paula, Sheean, Patricia M., Stolley, Melinda R.

“…Background: Prostate cancer (PC) is the most diagnosed non-skin cancer among men in the United States, with African American (AA) men experiencing the highest…”
Get full text

Association between copper transporter receptor 1(CTR1) expression and pathologic outcomes in cisplatin (Pt)-treated bladder cancer (BC) patients by Kilari, Deepak, Iczkowski, Kenneth, Robin, Adam, Pandya, Chintan, Bylow, Kathryn A., Langenstroer, Peter, Messing, Edward M., Guancial, Elizabeth A., Kim, Eric S.

“…Abstract only…”
Get full text

LETTERS TO THE EDITOR: TEMPORAL ARTERITIS: THE IMPORTANCE OF RECOGNIZING SENESCENT CHANGES VERSUS QUIESCENT DISEASE IN A TEMPORAL ARTERY BIOPSY by Bylow, Kathryn A, Brauner, Daniel J

Get full text